VacZine Analytics  
MarketVIEW: Gonococcal vaccines

Published: January 2024

Neisseria gonorrhoeae (Ng) is Gram-negative bacterium that caused ~82m new infections in 2020 (15-49 yrs) and is responsible for the 2nd most common sexually transmitted infection (STI), gonorrhea. Although mostly asymptomatic, in the female, ascending Ng infections can result in severe sexual reproductive health (SRH) outcomes of pelvic inflammatory disease (PID), ectopic pregnancy, and infertility. Ng infection can also elevate the risk for HIV acquisition/transmission and cause neonatal conjunctivitis which can cause blindness. Although Ng infections are generally treatable with antibiotics, the bacterium has a remarkable ability to acquire antimicrobial resistance against successive classes of antibiotics. This is considered a critical threat by the World Health Organisation (WHO).

A prophylactic Neisseria gonorrhoeae-specific vaccine impacting upon gonococcal infection could reduce adverse SRH outcomes and alleviate gonococcal AMR. It could be targeted routinely to adolescents/young adults or high-risk groups (GBMSM) associated with the highest number of diagnoses. Notable vaccines in development are GSK4348413 (Phase 1/2), the Gonovac project (Jenner Institute), Avacc-11 (Intravacc), EVX-B2 (Evaxion) and, Limmatech Bio AG (hexavalent approach). Meningococcal serogroup B vaccines notably GSKs Bexsero, 4CMenB and newer pentavalent approaches will have global utility due to OMV and NHBP components.

This MarketVIEW product is a comprehensive Executive Presentation (>225 slides, .pdf) and interactive MS-Excel forecast model (120 worksheets, .xls) which investigate the scenario-based uptake and commercial potential of Neisseria gonorrhoeae specific and menB vaccines across key target groups in 10 high-income nations (public/private) worldwide. A thorough review of the latest disease background/epidemiology/resistance trends data is presented along with discussion of latest understanding of vaccinology/R&D competitor landscape. The analysis contains an in-depth commercial assessment of potential Neisseria gonorrhoeae specific vaccine profiles with discussion around target population rationale, potential uptake, pricing, and clinical development feasibility/issues. A commercial investigation into the cross-protective capacity of monovalent and pentavalent meningococcal serogroup B vaccines is also included re: recent UK JCVI November 2023 policy.

THIS PRODUCT IS A SUMMARY PRESENTATION (~225 slides, .pdf) + 1 scenario-based interactive MS Excel Workbook(s)
Photo credit(s): Zach-vessels (@unsplash license)

To order please contact your region account manager, buy "on-line" or order direct at: orders@vaczine-analytics.com

CAT No: CONTENTS: PURCHASE:
VAMV091 Click here>> CONTACT US

*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW. For UK orders VAT will be added at 20%. On-line prices may include discounts and are converted from list price in US dollars (subject to currency fluctuations). Please review the TERMS and CONDITIONS of purchase.

Return to main list>> Questions about this report?






© 2022 VacZine Analytics. All rights reserved. Disclaimer | Privacy | Terms and conditions. hosted by chillydomains